Zimmer was required to divest certain assets due to merger with Biomet. Thats likely why lima got those assets. Notice in the article Lima acquired some Biomet assets as well.
Kyocera is a testing partner, that was disclosed in 2017. However Kyocera did not donate IP in this case and unless I'm mistaken, Sintx plans to use the testing results to submit to FDA. if thats the case it should need Zimmer as a commercialization partner. I highly doubt Zimmer will sell its liners to Kyocera so Kyocera can kick its butt in the hip market. No logic there as Hip is Zimmers bread n butter. Not to mention the 2011 quote stating specifically Zimmer was eyeing Si3N4 for next gen hip&knee implants.
Do you think Zimmer will plan to compete against Si3N4 head/coatng with AMC heads and maybe a CrN/NbN coating? As far as ive seen CrN/NbN is another bioinert substance that appears to be years away from marketability. Unless of course it doesnt need any human studies.
Bioinert vs bioactive? AMC suffer phase stability issues, cracking, & roughening problems. Not sure those are the best to market against Si3N4 femoral heads.
For some reason Pezzotti published a recent study on AMC liners. Coincidence maybe?
News 
Market Data 
Discover 
AI
